Ask AI
ASCO 2025 Breast Cancer

CE / CME

Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: July 31, 2025

Expiration: January 30, 2026

Activity

Progress
1 2
Course Completed

References

  1. Cortés J, Hurvitz SA, Im S, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature Med. 2024;30:2208-2215.
  2. Swain S, Miles D, Kim S, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Lancet Oncol. 2020;21:519.
  3. Tolaney S, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr LBA1008.
  4. Metzger O, Mandrekar S, DeMichele A, et al. A randomized, open-label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract GS2-12.
  5. Cortés J, Garcia-Mosquera JJ, Antonarelli G, et al. A single-arm phase II trial to evaluate the efficacy & safety of subcutaneous pertuzumab & trastuzumab maintenance after induction treatment w/ trastuzumab deruxtecan (T-DXd) for previously untreated HER2-positive advanced breast cancer. aacrjournals.org/clincancerres/article/31/12_Supplement/P5-03-11/753974/Abstract-P5-03-11-DEMETHER-A-single-arm-phase-II. Accessed July 25, 2025.
  6. Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475-1495.
  7. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.
  8. Tolaney S, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr LBA109.
  9. Turner NC, Mayer E, Park YH, et al. Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr LBA4.
  10. Bidard F, Mayer EL, Park YH, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025;[Epub ahead of print].
  11. Turner NC, Im SA, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391:1584-1596.
  12. Turner NC, Im SA, Saura C, et al. INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC). Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr 1003.
  13. Jhaveri KL, Im S, Saura C, et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2025;393:151-161.
  14. Hamilton E, De Laurentis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr LBA1000.
  15. Campone M, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;[Epub ahead of print].
  16. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025;392:1189-1202.
  17. Curigliano G, O'Shaughnessy J, Bidard FC, et al. Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr 1001.
  18. Bidard F, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD Trial. J Clin Oncol. 2022;40:3246-3256.
  19. Rugo H, Tolaney S, Chan N, et al. Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr 1070.
  20. Gao HF, Li W, Wu Z, et al. De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr LBA500.
  21. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080-1091.
  22. Hortobagyi GN, Lacko A, Sohn J, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2025;36:149-157.
  23. Kalinsky K, Reinisch M, Lu YS, et al. Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. Abstr 516.